246 related articles for article (PubMed ID: 15300212)
1. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
3. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
[TBL] [Abstract][Full Text] [Related]
4. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
5. mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members.
Chada S; Mhashilkar AM; Liu Y; Nishikawa T; Bocangel D; Zheng M; Vorburger SA; Pataer A; Swisher SG; Ramesh R; Kawase K; Meyn RE; Hunt KK
Cancer Gene Ther; 2006 May; 13(5):490-502. PubMed ID: 16282987
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
8. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
11. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells.
Mhashilkar AM; Stewart AL; Sieger K; Yang HY; Khimani AH; Ito I; Saito Y; Hunt KK; Grimm EA; Roth JA; Meyn RE; Ramesh R; Chada S
Mol Ther; 2003 Aug; 8(2):207-19. PubMed ID: 12907143
[TBL] [Abstract][Full Text] [Related]
12. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms.
Kawabe S; Nishikawa T; Munshi A; Roth JA; Chada S; Meyn RE
Mol Ther; 2002 Nov; 6(5):637-44. PubMed ID: 12409262
[TBL] [Abstract][Full Text] [Related]
14. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
15. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
16. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
17. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated ING4/IL-24 double tumor suppressor gene co-transfer enhances antitumor activity in human breast cancer cells.
Zhao Y; Li Z; Sheng W; Miao J; Yang J
Oncol Rep; 2012 Oct; 28(4):1315-24. PubMed ID: 22842937
[TBL] [Abstract][Full Text] [Related]
19. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
[TBL] [Abstract][Full Text] [Related]
20. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
